Oracle's impeccable results come at a high price.

Oracle surpassed estimates for the quarter, and lifted its guidance for fiscal 2027 revenue. During the quarter, Oracle announced plans to raise $45 billion to $50 billion in the fiscal year to expand ...

Recursion Pharmaceuticals (RXRX) has drawn attention after recent trading, with the share price closing at US$3.42 and short term returns showing pressure over the past week, month and past 3 months.

Oracle's OCI revenue is growing 66% YOY, outpacing AWS and Azure. Oracle is selling profitable business units and accumulating tens of billions in debt to fund the data center expansion needed to ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Oracle (ORCL) stock jumped 9% after earnings beat. See Oracle-linked ETFs ranked by YTD returns plus Quant ratings to spot winners & laggards—read now.

Oracle (NYSE: ORCL) shares declined by 5.8% as of 11:30 a.m this morning. The stock is now down more than 28% this year as of the time of writing. Why is Oracle stock declining in 2026 There's little ...

The $840 billion startup’s ⁠wildly successful partnership with Microsoft contains a prenuptial agreement triggered when artificial general intelligence is achieved. Snag is, ‌the ⁠definition and its ...

Dozens of hospitals have had their patient data compromised by a 2025 breach of Oracle Health’s legacy Cerner systems. Health systems continue to alert patients of the hack that occurred as early as ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...